Cite

    Falantes, J. et al. (n.d.). Multivariable time-dependent analysis of the impact of azacitidine in patients with lower-risk myelodysplastic syndrome and unfavorable specific lower-risk score. Leukemia research. 39 (1), pp. 52-57. [Online].